Advanced searches left 3/3

Car T Cell Therapy - Europe PMC

Summarized by Plex Scholar
Last Updated: 10 January 2023

* If you want to update the article please login/register

Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results.

The B-cell maturation antigen and Chimeric antigen receptor T-cell therapy have promising results in autoimmune diseases and may be novel therapies for relapsed/refractory neuromyelitis optica spectrum disorder (Microbiotic syndrome). The most common events of grade 3 or higher were hematologic toxic effects, which included hematologic toxic effects. In all patients, Cytokine release syndrome was identified, but there were no events of grade 1 or 2 observed. 11 patients had no relapse during the follow-up to a median 5. 5 months; all patients reported improvements in disabilities and quality-of-life; 11 patients' AQP-4 antibodies in serum showed a downward trend by the cutoff date; 11 patients' AQP-4 antibodies in serum showed a decline trend by the time. In summary, CAR T-cell therapy provides a dependable safety profile and therapeutic potentials for patients with relapsed/refractory AQP4-IgG seropositive NMOSD. Patients with other neuro-inflammatory disorders may also have other neuro-inflammatory diseases. CAR T-BCMA infusion in patients with other neuro-inflammatory diseases is now underway in order to determine the safety and effectiveness of the drug CAR T-BCMA infusion in patients with other neuro-inflammatory disorders.

Source link: https://europepmc.org/article/MED/36596762


Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma.

After radiation therapy with chimeric antigen receptor T-cell therapy and other cancer cell therapies, immunoe effector cell-associated neurotoxicity syndrome is a common disorder. Here, we present the cellular and tissue neuropathologic results of a patient who died from grade 4 ICANS after receiving anti-CD19 CAR T therapy for mantle cell lymphoma. A systematic review of glial subtypes reveals region-specific oligodendrocyte lineage cell loss as a potential cellular and pathophysiologic mediator in severe ICANS. Future elucidation of the mechanistic processes underlying ICANS will be vital in minimizing neurotoxicity caused by CAR T-cell and related immunotherapy regimens in oncologic and autoimmune disorders.

Source link: https://europepmc.org/article/MED/36592076


Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients.

Relapsed/refractory primary central nervous system lymphoma and secondary central nervous system lymphoma are both related to short life and represent unsatisfied need, requiring novel innovative approaches. In early reports, anti-CD19 chimeric antigen receptor T cells, which are used in systemic large B-cell lymphoma, have shown responses in PCNSL and SCNSL, but with limited sample size. Seventy percent of patients with PCNSL had CRS of any grade, and 53% had ICANS of any grade. 56% of the patients with PCNSL underwent complete remission with 37% remaining in remission at 6 months. The toxicity of anti-CD19-CAR T-cell therapy was similar to that of registrational studies in systemic LBCL with no increase in neurotoxicity observed. There were no discernible differences between PCNSL and SCNSL in patients with CNS lymphoma, with no apparent differences between PCNSL and SCNSL.

Source link: https://europepmc.org/article/MED/36260735


Characterization of Leukemic Resistance to CD19-Targeted CAR T-cell Therapy through Deep Genomic Sequencing.

A clinical breakthrough for pediatric B-cell acute lymphoblastic leukemia has been achieved, with the loss of the CD19 antibody target antigen in leukemic cells as a significant cause of relapse. We show that relapse-specific single-nucleotide variants and small indels treated with CAR T-cell therapy, 8 of whom died of CD19-relapse and 5 of whom developed CD19+ relapse, as well as deletions in the CD19 gene in a manner specific to those patients with CD19-relapse. One patient was discovered to have a pre-existing CD19 deletion in the context of genomic instability, which likely was the first attack leading to the patient's subsequent CD19-relapse.

Source link: https://europepmc.org/article/MED/36255409


Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.

Patients with severe B-cell lymphoma disease after chimeric antigen receptor T-cell therapy failure. Following CAR T failure, we report a multicenter retrospective study assessing the effectiveness, toxicities, and outcomes of alloHCT in LBCL patients following CAR T failure. One of the median number of lines of therapy between CAR T infusion and alloHCT was one. CAR T and alloHCT, as well as complete responses at the time of alloHCT were associated with improved outcomes on multivariate analysis, 2 lines of intervening therapy between CAR T and alloHCT, and complete response at the time of alloHCT were found with improved outcomes. In conclusion, alloHCT following CAR T failure can result in stable remissions in a subset of patients.

Source link: https://europepmc.org/article/MED/35833303


Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies.

The emergence of several novel therapeutic approaches has changed the therapeutic perspective of human malignancies over the past decade. Various medical uses have been established for various human malignancies, including the design of T cells to recognize tumor-specific membrane antigens and, as a result, death of cancer cells. However, CAR-T-cell therapy of hematological malignancies has been shown to various side effects.

Source link: https://europepmc.org/article/MED/36583504


Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy.

Background: For patients with relapsed/refractory large B-cell lymphoma receiving Chimeric Antigen Receptor T-cell therapy, it is important to find semi-quantitative and quantitative Positron Emission Tomography/Magnetic Resonance imaging results of both tumor and non-malignant lymphoma. Methods A single-center prospective review of 16 r/r LBCL patients undergoing CD19-targeted CAR T-cell therapy revealed differences. Maximum Standardized Uptake Values, mean SUV, Metabolic Tumor Volume, Tumor Lesion Glycolysis, total tumor burden, and Mean Apparent Diffusion Coefficient were among Tumor metrics reported in this report. The correlation between extracted metrics and PFS and OS was tested by an experimental Cox regression study. The Pre-therapy bone marrow SUV mean was related to PFS and OS. Conclusions MTV, tumor ADC mean, and FDG uptake in bone marrow unaffected by tumor infiltration are potential PET/MR metrics for predicting PFS and OS in r/r LBCL treated with CAR T-cells.

Source link: https://europepmc.org/article/MED/36575477


Current state of CAR-T therapy for T-cell malignancies.

It has been approved for relapsed/refractory B-cell lymphomas in Chimeric antigen receptor T-cell therapy, which has greatly improved disease outcomes. Normal T-cells commonly share mutual antigens with malignant cells, causing fratricide and significant T-cell aplasia, which is one of the key issues. Also, malignant T-cells obtained for CAR transduction could be contaminated by T-cells collected for CAR transduction. To prevent tumor formation, Allogeneic CAR-T products and CAR-NK-cells are expected to avoid tumor formation. Herein, we review the latest advancements in promising target antigens, the recent findings of CAR-T therapy clinical trials in T-cell malignancies, T-cell lymphomancies, the barriers of CAR-T therapy in T-cell malignancies, T-cell malignancies, and the solutions to these problems.

Source link: https://europepmc.org/article/MED/36601636


Allogeneic CD34 + selected hematopoietic stem cell boost following CAR T-cell therapy in a patient with prolonged cytopenia and active infection.

We administered a CD34+ hematopoietic stem cell transplant from his transplant donor, which resulted in hemogloboietic recovery and resolution of his infections without any effect on CD19-CAR T cells' activity. Following CD19-CAR T-cell therapy, a safe and effective option to address hematotoxicity can be provided by HSCB.

Source link: https://europepmc.org/article/MED/36565276


Systematic interrogation of tumor cell resistance to CAR T cell therapy in pancreatic cancer.

B cell malignancies can have dramatic clinical outcomes as a result of chimeric antigen receptor T cell therapy. To date, early clinical trials with CAR T cell therapy in non-B cell malignancies have been disappointing, indicating that tumor intrinsic characteristics may play a role in resistance. In particular, the absence of the majority of the genes responsible for GPI-anchor biosynthesis and attachment abrogated CAR T cells' ability to attack pancreatic cancer cells, indicating that disruption of this pathway might enable MSLN CAR T cell evasion in the clinic. Members of the death receptor pathway as well as genes that control tumor transcriptional responses, such as TFAP4 and INTS12. CAR T cell resistance to CAR T cell therapy is likely due to genetic changes in tumor intrinsic states, not a factor p65, according to NFu03baB transcription factor p65, suggesting that tumor resistance to CAR T cell therapy could be related to genetic changes in tumor intrinsic states.

Source link: https://europepmc.org/article/MED/36548402

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions